FTSE 100: Index falls as earnings results weigh; pound below $1.33, Bodycote soars
Investing.com -- Iradimed Corporation (NASDAQ:IRMD) saw its stock jump 5.6% after reporting first quarter earnings that exceeded analyst expectations, driven by strong revenue growth and improved profitability.
The MRI-compatible medical device maker posted adjusted earnings per share of $0.42 for Q1 2025, beating the consensus estimate of $0.41. Revenue came in at $19.5 million, surpassing analysts’ projections of $19.13 million and marking an 11% increase YoY.
"We are excited to begin 2025 with our fifteenth consecutive quarter of record revenue," said Roger Susi, President and CEO of Iradimed. He noted the company’s "impressive top-line performance" and 16% rise YoY in diluted EPS.
For Q2 2025, Iradimed expects revenue between $19.7 million and $19.9 million, with adjusted EPS of $0.41 to $0.44. The company reaffirmed its full-year 2025 guidance, projecting revenue of $78 million to $82 million and adjusted EPS of $1.71 to $1.81.
The company reported strong domestic sales, accounting for 82% of total revenue compared to 76% in the same quarter last year. Gross profit margin remained steady at 76.1%.
Iradimed also declared a quarterly cash dividend of $0.17 per share, payable on May 30, 2025.
With its new manufacturing facility on track for completion in July 2025, Iradimed appears well-positioned to support planned growth and build on its strong Q1 performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.